Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2022 and recent updates.
First Quarter Fiscal Year 2023 and Subsequent Highlights:
- Announced positive interim data for ANEB-001 from Part B of its Phase 2 clinical trial for Acute Cannabinoid Intoxication in September, 2022
- Announced $6.6 million private placement financing in September, 2022
- Announced the appointment of Nat Calloway, Ph.D. to Board of Directors
- Company Executives are scheduled to participate in the following investor conferences:
- Benchmark Discovery Conference, December 1, 2022
- J.P. Morgan 41st Annual Healthcare Conference 2023, January 9-12, 2023
- BIO CEO and Investor Conference, February 6-9, 2023
Management Commentary
“We remain very pleased that Part B of our ongoing Phase 2 clinical trial is progressing on schedule and we look forward to announcing additional results in the near future,” stated Simon Allen, Chief Executive Officer of Anebulo. “Preparations are ongoing for an observational study in ACI subjects in the emergency department setting to further support the PK/PD model and ANEB-001 development.”
Financial Results for the three months ended September 30, 2022
- Operating expenses in the first quarter of fiscal 2023 were $2.6 million compared with $1.6 million in the same period in fiscal 2022.
- Net loss in the first quarter of fiscal 2023 was $2.6 million, or $(0.11) per share, compared with a net loss of $1.6 million, or $(0.07) per share, in the first quarter of fiscal 2022.
- Cash burn in the first quarter of fiscal 2023 was $2.0 million.
- Cash was $19.2 million as of September 30, 2022.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.
|
|
|
|
|
|
|
Condensed Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
June 30,
|
|
|
|
2022
|
|
|
2022
|
|
Cash
|
|
$
|
19,213,697
|
|
$
|
14,548,471
|
|
Total assets
|
|
|
19,815,365
|
|
|
15,579,431
|
|
Total liabilities
|
|
|
698,179
|
|
|
512,531
|
|
Total stockholders’ equity
|
|
|
19,117,186
|
|
|
15,066,900
|
|
|
|
|
Condensed Statements of Operations
|
|
|
|
Three Months Ended September 30,
|
|
|
|
2022
|
|
2021
|
|
Research and development
|
|
$
|
1,223,776
|
|
|
$
|
715,098
|
|
|
General and administrative
|
|
|
1,388,271
|
|
|
|
839,826
|
|
|
Total operating expenses
|
|
|
2,612,047
|
|
|
|
1,554,924
|
|
|
Loss from operations
|
|
|
(2,612,047
|
)
|
|
|
(1,554,924
|
)
|
|
|
|
|
|
|
|
|
|
Other income, net
|
|
|
212
|
|
|
|
1,529
|
|
|
Net loss
|
|
$
|
(2,611,835
|
)
|
|
$
|
(1,553,395
|
)
|
|
Weighted average common shares outstanding, basic and diluted
|
|
|
23,416,495
|
|
|
|
23,344,567
|
|
|
Net loss per share, basic and diluted
|
|
$
|
(0.11
|
)
|
|
$
|
(0.07
|
)
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005403/en/